Cabaletta Bio (CABA) to Release Quarterly Earnings on Wednesday

Cabaletta Bio (NASDAQ:CABA) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect Cabaletta Bio to post earnings of ($0.67) per share for the quarter.

Cabaletta Bio (NASDAQ:CABA) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.65). On average, analysts expect Cabaletta Bio to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cabaletta Bio Stock Performance

CABA opened at $1.32 on Wednesday. The firm has a market cap of $66.98 million, a price-to-earnings ratio of -0.61 and a beta of 2.72. Cabaletta Bio has a twelve month low of $0.99 and a twelve month high of $13.50. The firm’s 50-day simple moving average is $1.37 and its 200-day simple moving average is $2.26.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CABA. UBS Group cut their price target on shares of Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Guggenheim reiterated a “buy” rating and set a $23.00 price objective on shares of Cabaletta Bio in a research report on Tuesday, April 1st. Wells Fargo & Company decreased their price target on Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 1st. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Cabaletta Bio in a report on Tuesday, April 1st. Finally, Morgan Stanley decreased their price objective on shares of Cabaletta Bio from $30.00 to $22.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 1st. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $21.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cabaletta Bio stock. Invesco Ltd. grew its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) by 357.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 61,675 shares of the company’s stock after buying an additional 48,181 shares during the period. Invesco Ltd. owned 0.12% of Cabaletta Bio worth $85,000 at the end of the most recent reporting period.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.